Member Detail - DF/HCC

Dr. Meghan J Mooradian, MD

Claim this profile

Massachusetts General Hospital Cancer Center

Studies Melanoma
Studies Lung Cancer
5 reported clinical trials
9 drugs studied

Area of expertise

1Melanoma
Meghan J Mooradian, MD has run 4 trials for Melanoma. Some of their research focus areas include:
Stage IV
Stage III
2Lung Cancer
Meghan J Mooradian, MD has run 2 trials for Lung Cancer. Some of their research focus areas include:
Stage IV

Affiliated Hospitals

Image of trial facility.
Massachusetts General Hospital Cancer Center
Image of trial facility.
Massachusetts General Hospital

Clinical Trials Meghan J Mooradian, MD is currently running

Image of trial facility.

Cryoablation + Ipilimumab + Nivolumab

for Melanoma

The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy with a PD-1 inhibitor. The names of the study interventions involved in this study are: * Cryoablation (an interventional radiology procedure that freezes part of a tumor) * Ipilimumab (an immunotherapy) * Nivolumab (an immunotherapy)
Recruiting1 award Phase 221 criteria
Image of trial facility.

SX-682 + Pembrolizumab

for Melanoma

Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. This first study will enroll participants with melanoma, as melanoma cancer has been shown to be able to attract MDSCs. The study will begin to determine if SX-682 is a safe and effective treatment of melanoma. It is thought that SX-682 will block MDSCs from going to the cancer, and thus will allow a patient's own immune system to attack the cancer. The first participants enrolled in the study will receive for 21 days SX-682 as monotherapy. After 21 days participants will receive pembrolizumab therapy (an approved immunotherapy for melanoma) in combination with SX-682 for up to approximately 2 years. Once the safe dose level of SX-682 in combination with pembrolizumab is determined, the remaining participants will be enrolled at the highest safe dose level of SX-682, in combination with pembrolizumab. These participants will receive the combination therapy and be evaluated in the study for approximately 2 years.
Recruiting1 award Phase 121 criteria

More about Meghan J Mooradian, MD

Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Meghan J Mooradian, MD has experience with
  • Cryoablation
  • Ipilimumab
  • Nivolumab
  • Evaluation Of CtDNA
  • Core Needle Biopsy
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Meghan J Mooradian, MD specialize in?
Is Meghan J Mooradian, MD currently recruiting for clinical trials?
Are there any treatments that Meghan J Mooradian, MD has studied deeply?
What is the best way to schedule an appointment with Meghan J Mooradian, MD?
What is the office address of Meghan J Mooradian, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security